Clear to blue. Breakthrough! |
Over time, a firm competing in an
industry that is competitive will tend towards zero economic profits. Over the
long term, that means there will be exit from firms that have higher marginal
costs, as they will lose money as a price taker.
If a firm wants to remain a going
concern and they are not just a commodity producer, they should ideally become
a monopoly, so that they can set their price and quantity. That task is too
easily said but is difficult to accomplish. Any monopoly at a large scale will
face regulation and excessive attention from the state in terms of prices and
quantities produced.
Instead,
what a firm needs to do is to be constantly innovative. By being constantly
innovative, they can use first mover advantage to gain a temporary monopoly on
their new concepts. Even better is if a firm can use state protections like
patents, which grant a temporary monopoly on a product. One example is Viagra.
Viagra was the first drug that was popularly used to treat erectile dysfunction
in the United States. Its introduction was unlike any other drug in recent
memory, and it led to jokes and magazine covers. It also led to sales. Though
there are now competing drugs, Viagra is not just a chemical compound; it is a
brand in itself. It still controls almost 50% of its market, and in 2012
brought in over two billion dollars for Pfizer (“Viagra”).
The problem is that those temporary
monopolies lapse. Drug companies have to keep drugs in their research and
development pipeline because Viagras are few and far between. Many promising
compounds flame out somehwhere between the lab and human testing. Therefore, to
maintain its market position, drug companies have to innovate. Alternately,
they buy smaller companies working on promising compounds. The reality is that
the monopoly granted by a patent is temporary. The patent for Viagra will run
out in 2019 (“Viagra”), and Pfizer will have to replace that two billion
dollars with something else. Other companies will be able to make the chemical
equivalent of Viagra and the profit on Viagra will be lowered. There are other
strategies that drug companies use to extend their monopoly on drugs: they will
reformulate the delivery system and then rebrand it as something like “Viagra Extended
Release”. Moves like this stem the fall of economic rents from the patent protection
and the fading brand, but they are no substitute for new innovation and
differentiation.
A final thing to consider is the pricing
on your temporary monopoly. If a drug company has created some potentially
life-saving compound, the price of that compound would perhaps have a perfectly
inelastic demand curve. No matter what price the company charged, the demand
would be everyone who had the disease. Something close to this has happened
recently. Gilead released Sovaldi. It is a twelve-week regime that has a much
higher cure rate for Hepatitis with few side effects than current treatments.
Gilead used its monopoly to set the price high: 84,000 for the
twelve-week-course. That comes out to about a thousand dollars a pill when the
marginal cost of the making those pills is much less. This pricing has brought
out extra-market forces to bring pressure on the company. (“Who Deserves to Get
Them?”). A quirk of the
pharmaceutical industry is that many of its products are not paid for by the
end user, instead it is government agencies and insurance companies. Around the
world, they are imposing various forms of political pressure and price controls
on the drug. In spite of this pressure, Gilead realized over ten billion
dollars in revenue on Sovaldi alone (“Sales of Sovaldi”). Even though there was
much clamor, the company made the profits by their innovation. In addition,
they are not done. Gilead has more drugs in the pipeline for when Sovaldi is
tapped dry.
References
Appleby, J. (2014, May 2). New hepatitis C Drugs’ Price
Prompts an Ethical Debate: Who Deserves to Get Them?
Washington Post. Retrieved from http://www.washingtonpost.com/business/new-hepatitis-c-drugs-price-prompts-an-ethical-debate-who-deserves-to-get-them/2014/05/01/73582abc-cfac-11e3-937f-d3026234b51c_story.html
Pollack, A. (2015, Feb 3). Sales of Sovaldi, New Gilead Hepatitis C
Drug, Soar to $10.3 Billion. The New York Times. Retrieved from http://www.nytimes.com/2015/02/04/business/sales-of-sovaldi-new-gilead-hepatitis-c-drug-soar-to-10-3-billion.html
Wilson, J. (2013, March 27). Viagra: The Little Blue Pill That
Could. CNN. Retrieved from http://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html